Ginkgo Bioworks Holdings, Inc.
DNA- Exchange
- NYSE
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001830214
In the last 90 days, Ginkgo Bioworks Holdings, Inc. insiders filed 0 open-market purchases and 3 sales; 183 institutions reported holding it in 13F filings for Q2 2026, worth $359.2M in total; Viking Global Investors is the only superinvestor holding it.
Q3 2024 vs. Q2 2024
How the institutions holding Ginkgo Bioworks Holdings, Inc. changed between Q2 2024 and Q3 2024.
All holders in Q3 2024All holders in Q2 2024
| Measure | Q2 2024 | Of which not filed for Q3 2024 | Q3 2024 | Change |
|---|---|---|---|---|
| Holders | 315 | 4 | 159 | −152 |
| SharesConverted for a 1-for-40 split | 23.3M | 1.06M | 26.3M | +4.07M (+18.3%) |
| Value | $311.5M | $14.1M | $214.5M | −$82.9M (−27.9%) |
4 institutions that held it in Q2 2024 haven't filed for Q3 2024 yet. Not filing isn't selling, so the changes leave them out.
New holders (30)
Institutions that held Ginkgo Bioworks Holdings, Inc. at the end of Q3 2024 but not at the end of Q2 2024.
Sold out (182)
Institutions that held Ginkgo Bioworks Holdings, Inc. at the end of Q2 2024 and filed for Q3 2024 without it.
Showing the largest 100 of 182 by value.
Not filed for Q3 2024 yet (4)
Institutions that held Ginkgo Bioworks Holdings, Inc. at the end of Q2 2024 and haven't filed a 13F for Q3 2024. Not filing isn't selling, so they aren't counted as sold out.
| Institution | Shares, Q2 2024 | Value, Q2 2024 |
|---|---|---|
| BlackRock Inc. | 42,010,826 | $14.0M |
| Benjamin F. Edwards & Company, Inc. | 234,836 | $79.0K |
| Relative Value Partners Group, LLC | 30,625 | $10.2K |
| JPL Wealth Management, LLC | 10,000 | $3.34K |